Welcome! You are visiting the MyeloRx web site.

Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
About Us
 
 
MyeloRx is a development stage company with compounds derived from a natural product
 
The disease targets for the MyeloRx compounds are acute myeloid leukemia, pancreatic cancer and immune-based diseases
 
The MyeloRx compounds are secured by internally developed and in-licensed intellectual property